高级检索
    李冬, 岳成山, 胡勇, 董学良, 王利雄. VEGFR2-v2971位点基因多态性与贝伐珠单抗联合全脑放疗治疗非小细胞肺癌脑转移患者的疗效及其相关性研究[J]. 徐州医科大学学报, 2022, 42(4): 248-254. DOI: 10.3969/j.issn.2096-3882.2022.04.003
    引用本文: 李冬, 岳成山, 胡勇, 董学良, 王利雄. VEGFR2-v2971位点基因多态性与贝伐珠单抗联合全脑放疗治疗非小细胞肺癌脑转移患者的疗效及其相关性研究[J]. 徐州医科大学学报, 2022, 42(4): 248-254. DOI: 10.3969/j.issn.2096-3882.2022.04.003
    shu
    Correlation between VEGFR2-v2971 gene polymorphism and bevacizumab combined with whole brain radiotherapy for patients with non-small cell lung cancer brain me＜x＞tastases[J]. Journal of Xuzhou Medical University, 2022, 42(4): 248-254. DOI: 10.3969/j.issn.2096-3882.2022.04.003
    Citation: Correlation between VEGFR2-v2971 gene polymorphism and bevacizumab combined with whole brain radiotherapy for patients with non-small cell lung cancer brain me＜x＞tastases[J]. Journal of Xuzhou Medical University, 2022, 42(4): 248-254. DOI: 10.3969/j.issn.2096-3882.2022.04.003
    shu

    VEGFR2-v2971位点基因多态性与贝伐珠单抗联合全脑放疗治疗非小细胞肺癌脑转移患者的疗效及其相关性研究

    Correlation between VEGFR2-v2971 gene polymorphism and bevacizumab combined with whole brain radiotherapy for patients with non-small cell lung cancer brain me＜x＞tastases

      摘要
    • 摘要: 目的 研究基于贝伐珠单抗联合全脑放疗的非小细胞肺癌脑转移患者中VEGFR2-V297I位点基因多态性对其疗效的影响及其相关性分析。方法 收集2015年6月至2017年6月入住我院接受贝伐珠单抗并联合全脑放疗的晚期NSCLC脑转移患者141例，详细记录患者的性别、年龄、病理分型、ECOG得分、EGFR突变类型及生存资料，比较不同VEGFR2-V297I基因型患者基于贝伐珠单抗联合全脑放疗后进展及生存情况。 结果 （1）141例肺癌患者中有83例（58.87%）携带有CC基因型，49例（34.75%）携带有CT基因型，9例（6.38%）携带有TT基因型；符合Hardy-Weinberg平衡定律（χ2=0.21，P=0.90）；（2）近期疗效评价，CC型和CT/TT型患者的客观缓解率分别为48.19%和48.28%，疾病控制率分别为89.16%和91.38%，差异均无统计学意义（P>0.05）；（3）携有CC基因的中位无进展生存期为9.012（95%CI：8.260-9.764）个月，携带有CT/TT型患者中位PFS为6.741（95%CI：5.787-7.695）个月（Log-rank =10.240，P=0.001）；携有CC基因的中位生存期为19.236（95%CI：18.176-20.295）个月，携带有CT/TT型患者中位OS为17.285（95%CI：16.175-18.395）个月（Log-rank =5.456，P=0.02）；（4）Cox比例风险回归模型显示年龄、性别、ECOG评分、以及EGFR 2-V297I 位点均是影响患者PFS的独立危险因素。结论 VEGFR2-V297I位点基因多态性会影响非小细胞肺癌脑转移患者基于贝伐珠单抗联合全脑放疗的疗效，基因型CT/TT是其进展与死亡的独立危险因素。

       

      Abstract: ob＜x＞jective To study the effect of VEGFR2- V297I gene polymorphism on the efficacy and its correlation in patients with brain me＜x＞tastases from non-small cell lung cancer ba＜x＞sed on bevacizumab combined with whole brain radiotherapy. Methods A total of 141 patients with advanced NSCLC brain me＜x＞tastases who were admitted to our hospital from June 2015 to June 2017 and received bevacizumab combined with whole brain radiotherapy were collected. The gender, age, pathological type, ECOG score, and EGFR were recorded in detail Mutation types and survival data, to compare the progress and survival of patients with different VEGFR2- V297I genotypes ba＜x＞sed on bevacizumab combined with whole brain radiotherapy Results (1) Of the 141 patients with gastric cancer, 83 (58.87%) carried the CC genotype, 49 (34.75%) carried the CT genotype, and 9 (6.38%) carried the TT genotype; consistent with Hardy-Weinberg Law of equilibrium (χ2 = 0.21, P = 0.90); (2) In the recent evaluation of curative effects, the ob＜x＞jective response rates of patients with CC and CT / TT type were 48.19% and 48.28%, respectively, and the disease control rates were 89.16% and 91.38%, respectively, with no significant difference (P> 0.05); (3) The median PFS with the CC gene was 9.012 (95% CI: 8.260-9.764) months, and the median PFS for patients with CT / TT type was 6.741 (95% CI: 5.787-7.695) Month (Log-rank = 10.240, P = 0.001); The median OS with the CC gene was 22.351 (95% CI: 21.059-23.644) months, and the median OS for patients with the CT / TT type was 18.259 (95% CI: 16.623-19.895) months (Log-rank = 11.719, P = 0.001); (4) The Cox proportional hazard regression model showed that age, gender, ECOG score, and EGFR 2-V297I locus were independent risk factors affecting PFS in patients. Conclusion VEGFR2- V297I gene polymorphism can affect the efficacy of bevacizumab combined with whole brain radiotherapy in patients with brain me＜x＞tastases from non-small cell lung cancer. Genotype CT / TT is an independent risk factor for its progression and death.

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回